# User Flows

## Executive Summary

The **User Flows** document maps user journeys through Uniting Doctors, from first visit to engaged community member. These flows optimize for professional credibility, medical accuracy, and efficient information discovery while preserving anonymity.

---

## Core User Personas

### 1. Dr. Academic (Research-Focused Physician)

- **Goals**: Share research, discover cutting-edge studies, engage in evidence-based discussions
- **Pain Points**: Traditional journals slow, wants real-time feedback, needs visibility
- **Behavior**: Posts research summaries, cites extensively, engages in deep technical discussions

### 2. Dr. Community (Community Hospital Physician)

- **Goals**: Practical advice for common cases, learn from peers, quick clinical pearls
- **Pain Points**: Limited specialist access, time constraints, needs actionable information
- **Behavior**: Asks questions, upvotes practical answers, follows relevant specialties

### 3. Dr. Specialist (Academic Tertiary Center)

- **Goals**: Answer complex questions, establish reputation, stay current in niche area
- **Pain Points**: Wants to help but time-limited, needs recognition for expertise
- **Behavior**: Answers questions in specialty, shares complex cases, selective engagement

### 4. Dr. Resident (Training Physician)

- **Goals**: Learn rapidly, prepare for exams, understand real-world practice
- **Pain Points**: Information overload, uncertain about quality, imposter syndrome
- **Behavior**: Searches extensively, reads more than posts, saves content, asks clarifying questions

---

## Onboarding Flow

### A. New User Journey (Account Creation โ First Post)

```
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
โ                   LANDING PAGE                      โ
โ  "Where doctors share real medicine, anonymously"  โ
โ                                                     โ
โ  [Sign Up] [See Example Discussions]               โ
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
                      โ
                      โผ
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
โ              REGISTRATION SCREEN                    โ
โ                                                     โ
โ  Email: ___________________________________         โ
โ  Password: _________________________________        โ
โ                                                     โ
โ  โ I am a licensed healthcare professional         โ
โ                                                     โ
โ  [Create Account]                                   โ
โ                                                     โ
โ  Why verify? Ensures quality discussions.           โ
โ  Your identity is never public.                     โ
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
                      โ
                      โผ
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
โ            VERIFICATION SCREEN                      โ
โ                                                     โ
โ  Upload Verification Document:                      โ
โ  โข Medical license                                  โ
โ  โข DEA certificate                                  โ
โ  โข Hospital ID badge                                โ
โ                                                     โ
โ  OR                                                 โ
โ                                                     โ
โ  Enter NPI Number: __________                       โ
โ  [Auto-Verify]                                      โ
โ                                                     โ
โ  ๐ Encrypted โข Deleted after 30 days               โ
โ                                                     โ
โ  [Skip for Now] [Submit]                            โ
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
                      โ
                      โผ
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
โ            PROFILE SETUP SCREEN                     โ
โ                                                     โ
โ  What should we call you?                           โ
โ  Display Name: ______________ (anonymous)           โ
โ                                                     โ
โ  Specialty:                                         โ
โ  โ Internal Medicine  โ Surgery                    โ
โ  โ Pediatrics         โ Anesthesiology             โ
โ  [+ More]                                           โ
โ                                                     โ
โ  Practice Setting:                                  โ
โ  โ Academic Medical Center                         โ
โ  โ Community Hospital                               โ
โ  โ Private Practice                                 โ
โ  โ Resident/Fellow                                  โ
โ                                                     โ
โ  [Continue]                                         โ
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
                      โ
                      โผ
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
โ            INTEREST SELECTION                       โ
โ                                                     โ
โ  What topics interest you?                          โ
โ                                                     โ
โ  [#Cardiology] [#Sepsis] [#Diabetes]                โ
โ  [#Anticoagulation] [#Difficult Airway]             โ
โ  [#Palliative Care] [+ Browse All]                  โ
โ                                                     โ
โ  Follow specialties for personalized feed:          โ
โ  โ Emergency Medicine                               โ
โ  โ Critical Care                                    โ
โ  โ Infectious Disease                               โ
โ                                                     โ
โ  [Finish Setup]                                     โ
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
                      โ
                      โผ
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
โ            WELCOME TO YOUR FEED                     โ
โ                                                     โ
โ  โจ Get Started Challenges:                         โ
โ  โ Read 3 discussions (0/3) +10 rep                โ
โ  โ Make your first comment +25 rep                  โ
โ  โ Ask a question +15 rep                           โ
โ                                                     โ
โ  โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ         โ
โ                                                     โ
โ  ๐ฐ Top Discussion Today                            โ
โ  "Novel approach to refractory AFib..."             โ
โ  ๐ค CardioDoc1234 โข 2h ago โข 234 โฌ                  โ
โ                                                     โ
โ  ๐ Research: NEJM just published                   โ
โ  "SGLT2 inhibitors in heart failure..."            โ
โ  ๐ Read Paper โข ๐จ 45 comments                      โ
โ                                                     โ
โ  [Write a post] [Ask a question]                    โ
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
```

**Key Decisions**:

- **Early vs Late Verification**: Collect email early, allow exploration before verification
- **Anonymous from Start**: No real names ever displayed
- **Interest-Driven**: Personalized feed immediately
- **Gamification**: Challenges encourage first actions

---

## Core Content Flows

### B. Asking a Question Flow

```
User Action: Click [Ask a Question]
                      โ
                      โผ
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
โ              QUESTION COMPOSER                      โ
โ                                                     โ
โ  Title (concise, specific)                          โ
โ  ________________________________________________   โ
โ                                                     โ
โ  Question Details (full context)                    โ
โ  โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ  โ
โ  โ Patient: 45M with chest pain, no cardiac... โ  โ
โ  โ                                              โ  โ
โ  โ Labs: Troponin negative, EKG shows...       โ  โ
โ  โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ  โ
โ                                                     โ
โ  โ๏ธ PHI Check: No patient names/MRNs detected โ     โ
โ                                                     โ
โ  Tags:                                              โ
โ  [#Emergency-Medicine] [#Cardiology] [+ Add Tag]    โ
โ                                                     โ
โ  Evidence Level: โ Case-based  โ Research Q        โ
โ                                                     โ
โ  [Preview] [Post Question]                          โ
โ                                                     โ
โ  Tips:                                              โ
โ  โข Include relevant labs/imaging                    โ
โ  โข Specify what you've tried                        โ
โ  โข Tag appropriate specialties                      โ
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
                      โ
                      โผ
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
โ            QUESTION POSTED                          โ
โ                                                     โ
โ  โ Question posted successfully!                    โ
โ                                                     โ
โ  ๐ฅ Notified:                                       โ
โ  โข 234 Emergency Medicine followers                 โ
โ  โข 89 Cardiology followers                          โ
โ                                                     โ
โ  ๐ก Tip: Upvote helpful answers to thank experts    โ
โ                                                     โ
โ  [View Question] [Ask Another]                      โ
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
                      โ
                      โผ
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
โ            QUESTION PAGE                            โ
โ                                                     โ
โ  "45M with atypical chest pain - stress test?"      โ
โ  Asked by You โข Just now                            โ
โ                                                     โ
โ  [Full question details...]                         โ
โ                                                     โ
โ  โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ         โ
โ                                                     โ
โ  ๐ฌ Answers (0)                                     โ
โ                                                     โ
โ  "Be the first to answer..."                        โ
โ                                                     โ
โ  [Follow Question] [Share] [Edit]                   โ
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
```

**15 minutes later...**

```
Notification: ๐ EmergencyDoc89 answered your question
                      โ
                      โผ
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
โ            QUESTION WITH ANSWER                     โ
โ                                                     โ
โ  ๐ฌ Answers (1)                                     โ
โ                                                     โ
โ  โฒ234 โ EmergencyDoc89 โข 980 reputation            โ
โ  โ      โ๏ธ Verified: Emergency Medicine             โ
โ  โ                                                  โ
โ  โ  "Given negative troponin and atypical          โ
โ  โ  features, consider PERC rule for PE            โ
โ  โ  risk stratification..."                        โ
โ  โ                                                  โ
โ  โ  [1] JAMA 2008;299(22):2463 (PERC rule)        โ
โ  โ  [2] Circulation 2011;123:e369 (UA/NSTEMI)     โ
โ  โ                                                  โ
โ  โโ [Reply] [Upvote] [Accept Answer]                โ
โ                                                     โ
โ  ๐ก Accept this answer if it solved your question   โ
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
```

**Key Features**:

- **PHI Detection**: Automated check before posting
- **Tag Suggestions**: ML suggests relevant specialties
- **Notification Routing**: Alerts targeted experts
- **Accept Answer**: Signals resolution, rewards answerer

---

### C. Sharing Research Flow

```
User discovers paper โ Shares to platform
                      โ
                      โผ
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
โ              SHARE RESEARCH                         โ
โ                                                     โ
โ  Import from PubMed:                                โ
โ  PMID: _________ [Fetch]                            โ
โ                                                     โ
โ  OR paste DOI:                                      โ
โ  DOI: _________ [Fetch]                             โ
โ                                                     โ
โ  OR enter manually:                                 โ
โ  Title: _______________________________________     โ
โ  Authors: _____________________________________     โ
โ  Journal: _________________ Year: _______           โ
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
                      โ (Fetches metadata)
                      โผ
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
โ              ADD COMMENTARY                         โ
โ                                                     โ
โ  ๐ NEJM 2024: "SGLT2 Inhibitors in HFpEF"          โ
โ  Johnson et al. | PMID: 12345678                    โ
โ                                                     โ
โ  Your Take (optional):                              โ
โ  โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ  โ
โ  โ This changes my practice for HFpEF patients  โ  โ
โ  โ with DM. Key takeaway: 25% mortality         โ  โ
โ  โ reduction with empagliflozin...              โ  โ
โ  โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ  โ
โ                                                     โ
โ  Clinical Relevance:                                โ
โ  โ Changes practice                                 โ
โ  โ Controversial finding                            โ
โ  โ Confirms existing evidence                       โ
โ                                                     โ
โ  Tags: [#Cardiology] [#Heart-Failure] [#SGLT2]      โ
โ                                                     โ
โ  [Post to Feed]                                     โ
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
                      โ
                      โผ
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
โ              RESEARCH POST (FEED)                   โ
โ                                                     โ
โ  ๐ค CardiologyDoc2024 โข 1h ago                      โ
โ  โ๏ธ Verified: Cardiology                            โ
โ                                                     โ
โ  ๐ NEJM 2024: "SGLT2 Inhibitors in HFpEF"          โ
โ                                                     โ
โ  "This changes my practice for HFpEF patients..."   โ
โ                                                     โ
โ  ๐ [Read Full Text] (Open Access via Unpaywall)    โ
โ  ๐ [View Figures]                                  โ
โ                                                     โ
โ  Evidence: Level 1a (Systematic Review)             โ
โ                                                     โ
โ  โฒ 189 โฌ  ๐ฌ 34 comments  ๐ Save  ๐ค Share         โ
โ                                                     โ
โ  โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ         โ
โ                                                     โ
โ  Top Comment by NephroExpert:                       โ
โ  "Important to note CKD subgroup analysis..."       โ
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
```

**Key Features**:

- **Automated Metadata**: Fetches paper details from PubMed
- **Open Access Detection**: Unpaywall API finds free versions
- **Evidence Tagging**: Classifies study type
- **Clinical Relevance**: Signals practice-changing findings

---

### D. Discovering Content Flow

```
User searches: "refractory septic shock"
                      โ
                      โผ
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
โ              SEARCH RESULTS                         โ
โ                                                     โ
โ  "refractory septic shock"                          โ
โ  โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ    โ
โ                                                     โ
โ  Filter: [All] [Questions] [Research] [Cases]       โ
โ  Sort: [Relevance] [Recent] [Most Voted]            โ
โ                                                     โ
โ  โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ         โ
โ                                                     โ
โ  ๐ฅ Top Result                                      โ
โ  "Methylene blue in distributive shock"             โ
โ  ๐ค ICU_Intensivist โข 456 โฌ โข 89 comments           โ
โ  Evidence: Level 1b (RCT)                           โ
โ  โ๏ธ Verified: Critical Care                         โ
โ                                                     โ
โ  Excerpt: "...vasopressin-refractory shock,         โ
โ  consider methylene blue 1-2mg/kg..."               โ
โ                                                     โ
โ  โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ         โ
โ                                                     โ
โ  ๐ Recent Research                                 โ
โ  "Angiotensin II in Septic Shock (ATHOS-3)"        โ
โ  NEJM 2023 โข 234 citations โข Shared 45 times        โ
โ                                                     โ
โ  โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ         โ
โ                                                     โ
โ  ๐ฌ Question                                        โ
โ  "Patient on 4 pressors, pH 6.9 - ECMO?"           โ
โ  Asked 2d ago โข 23 answers                          โ
โ                                                     โ
โ  [Load More Results]                                โ
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
```

**Hybrid Search** (Elasticsearch + Semantic):

1. Keyword match: "septic shock", "refractory"
2. Semantic expansion: Related terms (distributive shock, vasoplegic)
3. Ranking: Reputation + recency + votes + relevance

---

### E. Building Reputation Flow

```
New User (0 reputation) โ Engaged Expert (1000+ reputation)

Action Taken                    Reputation Change
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
Account verified                     +50
First quality post                   +25
Post receives upvote                 +10
Post heavily upvoted (50+)          +100
Answer accepted                      +50
Question receives upvote             +5
Comment receives upvote              +2
Research shared (cited)             +15
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
Cumulative: 1000+ โ Trusted Expert
```

**Reputation Milestones**:

```
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
โ              REPUTATION MILESTONES                  โ
โ                                                     โ
โ  Your Reputation: 1,240                             โ
โ  Rank: Trusted Expert (Top 5%)                      โ
โ                                                     โ
โ  โโโโโโโโโโโโโโโโโโโโ                               โ
โ  Next: Senior Expert (1,500)                        โ
โ                                                     โ
โ  Unlocked Privileges:                               โ
โ  โ Vote on posts (50 rep)                           โ
โ  โ Comment anywhere (100 rep)                       โ
โ  โ Edit community wiki (500 rep)                    โ
โ  โ Vote to close low-quality (1,000 rep)            โ
โ  โณ Access moderation tools (1,500 rep)              โ
โ                                                     โ
โ  Recent Activity:                                   โ
โ  โข Answer accepted: +50                             โ
โ  โข Post upvoted 8x: +80                             โ
โ  โข Research cited by 5 users: +75                   โ
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
```

**Key Gamification**:

- **Clear Progress**: Visual reputation bar
- **Privilege Unlocks**: New abilities motivate engagement
- **Transparency**: Show how reputation was earned

---

## Moderation Flows

### F. Reporting Content Flow

```
User sees problematic post โ Reports
                      โ
                      โผ
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
โ              REPORT CONTENT                         โ
โ                                                     โ
โ  Why are you reporting this?                        โ
โ                                                     โ
โ  โ Medical misinformation                           โ
โ  โ Spam or advertising                              โ
โ  โ Harassment or abuse                              โ
โ  โ Patient privacy violation (PHI)                  โ
โ  โ Off-topic / Low quality                          โ
โ  โ Other: __________________                        โ
โ                                                     โ
โ  Additional context (optional):                     โ
โ  โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ  โ
โ  โ This recommends stopping insulin for T1DM   โ  โ
โ  โ patients, which is dangerous advice.        โ  โ
โ  โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ  โ
โ                                                     โ
โ  [Cancel] [Submit Report]                           โ
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
                      โ
                      โผ
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
โ              REPORT SUBMITTED                       โ
โ                                                     โ
โ  โ Thank you for helping keep the community safe    โ
โ                                                     โ
โ  Your report has been submitted to moderators.      โ
โ  We'll review within 24 hours.                      โ
โ                                                     โ
โ  Report ID: #REP-45782                              โ
โ                                                     โ
โ  [Track Report Status]                              โ
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
                      โ
                      โผ (Moderator Review)
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
โ            MODERATION QUEUE                         โ
โ                                                     โ
โ  Report #REP-45782                                  โ
โ  Type: Medical Misinformation                       โ
โ  Reported by: User #12345 (450 rep)                 โ
โ  Post by: AnonymousDoc789 (120 rep)                 โ
โ                                                     โ
โ  โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ         โ
โ                                                     โ
โ  Reported Content:                                  โ
โ  "For Type 1 diabetics, try stopping insulin..."   โ
โ                                                     โ
โ  Reporter Note:                                     โ
โ  "Dangerous advice - T1DM requires insulin"         โ
โ                                                     โ
โ  โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ         โ
โ                                                     โ
โ  Moderator Actions:                                 โ
โ  [Remove Post] [Issue Warning] [Dismiss Report]     โ
โ  [Ban User] [Request Peer Review]                   โ
โ                                                     โ
โ  Similar Past Reports: 2 (same user)                โ
โ  AI Risk Score: HIGH (0.89)                         โ
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
                      โ (Moderator removes post)
                      โผ
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
โ              REMOVAL NOTIFICATION                   โ
โ                                                     โ
โ  Your post was removed                              โ
โ                                                     โ
โ  Reason: Dangerous medical misinformation           โ
โ                                                     โ
โ  Specific Issue:                                    โ
โ  Recommending discontinuation of life-saving        โ
โ  medication (insulin for Type 1 diabetes)           โ
โ  violates Community Guidelines ยง 3.2                โ
โ                                                     โ
โ  This is your 1st violation.                        โ
โ  Reputation: -50 points                             โ
โ                                                     โ
โ  Further violations may result in suspension.       โ
โ                                                     โ
โ  [Appeal Decision] [Acknowledge]                    โ
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
```

**Key Features**:

- **Fast Reporting**: 2-click process
- **Moderator Context**: AI risk score + past reports
- **User Education**: Explain why content removed
- **Appeal Process**: Fair dispute resolution

---

## Mobile Experience Flows

### G. Mobile App Navigation

```
โโโโโโโโโโโโโโโโโโโโโโโโ
โ  ๐ฑ MOBILE APP       โ
โ                      โ
โ  โโโโโโโโโโโโโโโโโ   โ
โ  โ Uniting Doctorsโ   โ
โ  โโโโโโโโโโโโโโโโโ   โ
โ                      โ
โ  ๐ For You          โ
โ  โโโโโโโโโโโโโโโโโโ  โ
โ  ๐ฐ Post 1           โ
โ  โฌ189 ๐ฌ34 ๐        โ
โ  โโโโโโโโโโโโโโโโโโ  โ
โ  ๐ฐ Post 2           โ
โ  โฌ234 ๐ฌ67 ๐        โ
โ  โโโโโโโโโโโโโโโโโโ  โ
โ                      โ
โ  [โ Quick Post]     โ
โ                      โ
โ  โโโโโโโโโโโโโโโโโโ  โ
โ  ๐ Feed             โ
โ  ๐ Search           โ
โ  ๐ Notifications    โ
โ  ๐ค Profile          โ
โโโโโโโโโโโโโโโโโโโโโโโโ
```

**Mobile-Optimized Features**:

- **Swipe Actions**: Swipe right to upvote, left to save
- **Tap to Expand**: Collapsed long posts
- **Voice Input**: Dictate questions (hands-free for busy clinicians)
- **Offline Mode**: Cache recent content, sync when online
- **Push Notifications**: Critical updates, answered questions

---

## Advanced Flows

### H. Creating a Clinical Series

```
Expert wants to create multi-part educational content
                      โ
                      โผ
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
โ              CREATE SERIES                          โ
โ                                                     โ
โ  Series Title:                                      โ
โ  "Anticoagulation Mastery: 10-Part Series"          โ
โ                                                     โ
โ  Description:                                       โ
โ  "Comprehensive guide to anticoagulation            โ
โ  management in complex scenarios..."                โ
โ                                                     โ
โ  Planned Posts:                                     โ
โ  1. Introduction to DOACs vs Warfarin               โ
โ  2. Managing bleeding complications                 โ
โ  3. Bridging strategies                             โ
โ  4. Special populations (CKD, liver disease)        โ
โ  [+ Add More]                                       โ
โ                                                     โ
โ  Publishing Schedule:                               โ
โ  โ Weekly (every Monday)                            โ
โ                                                     โ
โ  [Create Series]                                    โ
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
                      โ
                      โผ
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
โ              SERIES LANDING PAGE                    โ
โ                                                     โ
โ  ๐ Anticoagulation Mastery                         โ
โ  by AnticoagExpert (2,300 rep)                      โ
โ                                                     โ
โ  10 parts โข 234 followers โข 45 hours content        โ
โ                                                     โ
โ  [Follow Series]                                    โ
โ                                                     โ
โ  โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ         โ
โ                                                     โ
โ  โ Part 1: Introduction to DOACs (Published)       โ
โ  โณ Part 2: Bleeding complications (Next Monday)    โ
โ  ๐ Part 3: Bridging strategies (Draft)             โ
โ  [ ] Part 4-10: Coming soon                         โ
โ                                                     โ
โ  ๐ฌ Discussion Forum (67 comments)                  โ
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
```

**Series Benefits**:

- **Structured Learning**: Follow educational paths
- **Reputation Boost**: High-quality series = major reputation
- **Notifications**: Followers alerted to new parts
- **Discoverability**: Series featured in platform

---

## Success Metrics per Flow

### Onboarding

- **Activation Rate**: 70% complete profile setup
- **Time to First Action**: <5 minutes
- **Verification Rate**: 85% verify within 7 days

### Content Creation

- **Daily Active Posters**: 5% of users
- **Questions Answered**: 80% within 24 hours
- **Research Shared**: 50+ papers daily

### Discovery

- **Search Success**: 90% find relevant content in 3 clicks
- **Time on Platform**: 15 min avg per session
- **Return Rate**: 60% weekly active users

### Moderation

- **Report Response**: 90% reviewed within 24 hours
- **False Reports**: <5%
- **User Appeals**: 20% of removals appealed, 15% overturned

---

## Accessibility Flows

### I. Screen Reader Experience

```
VoiceOver/JAWS User Navigation:
                      โ
                      โผ
"Main navigation landmark"
  โโ "Link: Home Feed"
  โโ "Link: Search"
  โโ "Link: Notifications, 3 unread"
  โโ "Link: Profile"
                      โ
                      โผ
"Article: Post by CardioDoc1234"
  โโ "Heading level 2: Novel approach to refractory AFib"
  โโ "Posted 2 hours ago"
  โโ "234 upvotes"
  โโ "Button: Upvote post"
  โโ "Button: Comment"
  โโ "Link: Read 45 comments"
```

**Keyboard Navigation**:

- `Tab`: Navigate focusable elements
- `Enter`: Activate buttons/links
- `Space`: Upvote (on vote button)
- `Shift+Tab`: Navigate backwards
- `Esc`: Close modals
- `/`: Focus search bar

---

## Conclusion

These user flows optimize for:

- **Rapid Onboarding**: Get users engaged quickly
- **Effortless Discovery**: Find relevant content easily
- **Quality Content Creation**: Tools for detailed, evidence-based posts
- **Reputation Building**: Clear path to expertise recognition
- **Community Safety**: Effective moderation flows
- **Mobile Excellence**: Native-quality mobile experience
- **Accessibility**: WCAG 2.1 AA compliant flows

**Next Steps**: Wireframe these flows in [WIREFRAMES.md](./WIREFRAMES.md)

---

**Document Version**: 1.0
**Last Updated**: November 8, 2025
**Owner**: Product & UX Team
**Related Documents**:

- [WIREFRAMES.md](./WIREFRAMES.md)
- [BRAND_IDENTITY.md](./BRAND_IDENTITY.md)
- [ONBOARDING_EXPERIENCE.md](../operations/ONBOARDING_EXPERIENCE.md)
